LIBI-Diagnostics

Company Overview

Snapshot

Founded in January 2020 by David Risin and Dr. Ayelet Ben Barak, LIBI-Diagnostics operates with 1–10 employees. The company has secured funding across one round from Headstart, and is focused on developing advanced cancer detection technologies.

Business overview

LIBI-Diagnostics is a gene-biomarker startup specializing in the early detection of cancer. The company utilizes state-of-the-art Next-Generation Sequencing (NGS) technology to customize tests for patients, detecting alterations of Aurora Kinase A in bio-liquid samples such as blood and voided urine. This approach aims to provide a practical and effective alternative to periodic imaging tests, enabling early diagnosis of recurrent cancerous development with minimal cells and offering sufficient information to neutralize early development, thereby sparing patients aggressive treatments. LIBI-Diagnostics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Test Diagnostics & Screening, serving the healthcare market and patients.

Company Intelligence Q&A

When was LIBI-Diagnostics founded?

LIBI-Diagnostics was founded in January 2020.

Who are the founders of LIBI-Diagnostics?

The company was founded by David Risin and Dr. Ayelet Ben Barak.

What is LIBI-Diagnostics' core technology?

LIBI-Diagnostics uses Next-Generation Sequencing (NGS) technology to detect gene-biomarkers for early cancer detection.

What type of funding has LIBI-Diagnostics received?

In October 2021, LIBI-Diagnostics received $100K in crowdfunding from Headstart.

What problem does LIBI-Diagnostics aim to solve?

LIBI-Diagnostics aims to provide early detection of recurrent cancerous development using non-invasive bio-liquid tests, offering an alternative to periodic imaging and potentially reducing the need for aggressive treatments.